Last updated on September 2017

Efficacy and Safety of Plasma Exchange With Albutein 5% in Patients With Amyotrophic Lateral Sclerosis


Brief description of study

This is a pilot, phase IIa, prospective, open-label, single-arm study to evaluate disease progression, forced vital capacity, and the safety and tolerability of plasma exchange (PE) using Albutein® 5% in subjects with amyotrophic lateral sclerosis (ALS).

Detailed Study Description

This is a phase IIa, prospective, open-label, single-arm pilot study to evaluate the efficacy and safety of PE with Albutein® 5% in subjects with ALS. The planned enrollment is 10 subjects who have a definite, possible, or probable diagnosis of ALS, according to the revised El Escorial criteria. Enrolled subjects will be treated with PE using Albutein 5% as a replacement solution during an Intensive Treatment Phase (2 PEs per week over 3 weeks) followed by a Maintenance Treatment Phase (weekly PE for 21 weeks) for a total treatment duration of 6 months. A 6-month follow up will begin after the last PE.

Clinical Study Identifier: NCT02872142

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Catherine L. Andrews

Dartmouth-Hitchcock Medical Center
Lebanon, NH United States
  Connect »